SCHEDULE: Janus Henderson Discloses 4% Stake in Tenax Therapeutics
Beneficial Ownership Report
Janus Henderson Group plc has reported a 4.0% beneficial ownership stake in Tenax Therapeutics, Inc., holding 166,666 shares of common stock.
Summary
- Janus Henderson Group plc, a Jersey-based entity, has disclosed a beneficial ownership of 166,666 shares of Common Stock in Tenax Therapeutics, Inc.
- This ownership represents 4.0% of the class of securities.
- Janus Henderson Group plc holds shared voting power and shared dispositive power over all 166,666 shares.
- The shares are held through indirect subsidiaries, JHIUS, JHIUKL, and JHIAIFML, which are registered investment advisers furnishing investment advice to Managed Portfolios.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Tenax Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, which is neutral in sentiment regarding the issuer's operational performance. The presence of an institutional investor can be seen as a minor positive signal, but the filing itself does not contain performance-related information.
Positives
- The disclosure of a 4.0% stake by an institutional investor like Janus Henderson Group plc indicates institutional interest and confidence in Tenax Therapeutics, Inc.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or operations.
Industry Context
This filing reflects a passive investment by a global asset manager in a publicly traded company, a common occurrence in the financial markets. It indicates that institutional investors are monitoring and taking positions in companies like Tenax Therapeutics, Inc.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 12/09/2022 | Date of Power of Attorney execution by Janus Henderson Group plc. |
| 06/30/2025 | Date of event which requires the filing of this statement. |
| 08/14/2025 | Date of signature for the Schedule 13G filing. |
Keywords
Tenax Therapeutics, Janus Henderson, Common Stock, SEC Filing, Schedule 13G, Institutional Ownership, Investment Adviser, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.